Top Back to top

Outcomes of patients treated with Ibrutinib post autologous stem cell transplant for mantle cell lymphoma.

Lymphoma Working Party (LWP)
Study number:
Short title:
PT Ibrutinib for MCL
Study status:
data collection
Deadline for data collection:
Study design:
Retrospective EBMT registry based analysis.
Primary objective:
To evaluate the outcomes of patients with MCL who receive Ibrutinib for relapse following the current standard first line therapy in fit patients (Rituximab containing induction regimes and ASCT in first response).
Key inclusion criteria:
Inclusion Criteria
• Age≥18 years at diagnosis
• Histological diagnosis of mantle cell lymphoma (MCL)
• First Autologous stem cell transplant
• Induction immunochemotherapy with a rituximab containing regimen
• Achieved a CR or PR after 1 or 2 lines of induction treatment
• ASCT in first response (CR/PR 1)
• Relapse on or after 1st October 2014 (date of European licence grant for ibrutinib) and before January 2017

Exclusion criteria
• Not treated with ibrutinib for relapse after ASCT
Principal investigator:
Steve Robinson / Claire Burney
Principal investigator email:
EBMT Study coordinator:
Hervé Finel / Irma Khvedelidze
Study coordinator email: